Zonisamide for the treatment of Parkinson’s disease

Abstract

Zonisamide is an antiepileptic drug widely used to treat seizures worldwide. In additrion to epilepsy, zonisamide may have beneficial efficacy in various neurological or psychiatric diseases. This article reviews the structure, mechanism of action, pharmacokinetics and possible antiparkinsonian action of zonisamide. A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan provided data suggesting that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson’s disease (PD). Zonisamide may be effective in reducing the duration of ‘off’ time in patients with PD treated with L-DOPA. The therapeutic doses of zonisamide for the treatment of PD are 50–100 mg/day, considerably lower than those for the treatment of epilepsy (200–400 mg/day). It is expected that zonisamide will be safe and tolerated in patients with PD, as it has been used as an antiepileptic for more than 15 years; however, further studies are required to evaluate its safety and tolerability in the treatment of PD. The pharmacological mechanisms of the beneficial actions of zonisamide in PD remain unclear. Various hypotheses have been proposed, but the supporting data are not yet sufficient to draw any conclusions. Further basic research is required to advance our understanding of the antiparkinsonian mechanism of zonisamide.

Keywords::

• antiepileptic drug
• Parkinson’s disease
• tremor
• zonisamide

Financial disclosure

The author has no relevant financial interests, including employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties related to this manuscript.